ArticleRadiation oncology (London, England)2026
Revisiting fractionation in prostate carbon ion therapy: first comparative analysis of biologically effective dose using mMKM with diverse parameters.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbon ion radiotherapy (CIRT) for prostate cancer has evolved from conventional regimens [66 Gy(RBE)/20 fractions (66G20), 63 Gy(RBE)/20 fractions (63G20)] toward hypofractionated schedules [57.6 Gy(RBE)/16 fractions (57.6G16), 51.6 Gy(RBE)/12 fractions (51.6G12), and 40 Gy(RBE)/4 fractions (40G4)]. Whether these are biologically equivalent remains unclear. To our knowledge, this is the first study to systematically evaluate the biological effects of these regimens using the modified microdosimetric kinetic model (mMKM) across diverse parameter settings.
methodsBiologically effective dose (BED) was calculated using four approaches: (1) photon linear-quadratic (LQ) model (2), modified microdosimetric kinetic model (mMKM) with human salivary gland parameters and fixed RBE of 2.41 (3), mMKM3.1, and (4) mMKM with varied domain radius (0.2–0.5 μm) and α/β (1.5–10 Gy). Tumor control probability (TCP) was further estimated based on a reanalysis of the Ion Prostate Irradiation trial.
resultsPhoton LQ analysis suggested near-equivalent BEDs for 63G20, 57.6G16, and 51.6G12 (~ 200 Gy and ~ 130 Gy for α/β = 1.5 and 3 Gy), with 40G4 markedly higher. In contrast, all mMKM-based methods showed progressive BED reductions with hypofractionation versus 63G20 (–16.8% to − 11.3% for 51.6G12; − 30.4% to − 5.2% for 40G4). TCP decreased by 15.5% for 51.6G12 and 28.7% for 40G4. mMKM also yielded higher effective α/β values for CIRT, reflecting reduced fractionation sensitivity.
conclusionsmMKM-based modeling challenges the assumption of dose equivalence in hypofractionated prostate CIRT, suggesting potential underdosing risks. This parameter-sensitive analysis underscores the need for biologically robust models to refine dose prescription and optimize outcomes in particle therapy. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.